IFW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Guitton et al. Application No.: 10/812,298 Filed: March 29, 2004 Examiner: Not yet assigned Art Unit: Not yet assigned

Title: METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR

EXCITOTOXICITY
Docket No.: AUR-2001US01

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with The United States Postal Service as First Class Mail in an envelope Addressed to Commissioner of Patents, R.O. Box 1450, Alexandria, VA 22313-1450 on

PIERCE ATWOOD

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[X] under 37 CFR 1.97(b), or

(Filed within three months of filing national application; within three months of date of entry of national stage of international application; or before mailing date of first office action on the merits; whichever occurs last)

[] under 37 CFR 1.97(c) together with either:
[] a Certification under 37 CFR 1.97(e), or
[] a \$180.00 fee set forth in 37 CFR 1.17(p), or

(Filed after the CFR 1.97(b) time period, but before final action or notice of allowance)

The undersigned hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.

[]	under [] []	37 CFR 1.97(d) together with: a Certification under 37 CFR 1.97(e), and a fee set forth in 37 CFR 1.17(p).	
		after final action or notice of allowance, which issue fee)	never occurs first, but before payment
Metho	d of Fe	e Payment:	
[]	Enclos	sed is a check in the amount of \$	·
[]	Please	e charge Deposit Account 500282 in the amou	unt of \$
[]	Two d	uplicate copies of this Statement are enclosed	d.
[X]	Please 50028	e charge any deficiency in fees and credit any 2.	overpayment to Deposit Account
Enclos	sed her	ewith is form PTO-1449:	
[X]	Copie	s of the cited references are enclosed.	
[]	Copie Serial Rule 9	s of cited references are enclosed except tho Nos, and references that are no 8.	se of record in prior applications, U.S. ot required to be submitted under
Concis	se Expl	anation Requirements:	
[]	The "d	concise explanation" requirement under C.F.F	R. 1.98(a)(3) is satisfied by:
	[]	the explanation provided on the attached sh	neet.
	[]	the explanation provided in the Specification	٦.
	It is re	quested that the information disclosed herein	be made of record in this application.
			Respectfully submitted,
			Mufuneel
			Kevin M. Farrell Attorney for Applicants Registration No. 35,505 (603) 433-6300
	mouth, I: 9\9		

P0059454.DOC

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 4

Complete if Known

Application Number 10/812,298

Filing Date March 29, 2004

First Named Inventor Matthieu Guitton

Art Unit Not yet assigned

Examiner Name Not yet assigned

Attorney Docket Number AUR-2001US01

<del></del>	1 04-	Do assessed Normalis :	Publication Date	DOCUMENTS  Name of Patentee or	Pages, Columns, Lines, Where
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	AA	US- 5,421,818	Jun-6-1995	Arenberg	
	AB	<sup>US-</sup> 5,474,529	Dec-12-1995	Arenberg	
	AC	<sup>US-</sup> 5,476,446	Dec-19-1995	Arenberg	
	AD	<sup>US-</sup> 5,716,961	Feb-10-1998	Sands	
	AE	<sup>US-</sup> 6,045,528	Apr-4-2000	Arenberg et al.	
	AF	<sup>US-</sup> 6,066,652	May-23-2000	Zenner et al.	
	AG	<sup>US-</sup> 6,120,484	Sep-19-2000	Silverstein	
	AH	<sup>US-</sup> 6,309,410	Oct-30-2001	Kuzma et al.	
	Al	<sup>US-</sup> 6,377,849	Apr-23-2002	Lenarz et al.	
	AJ	<sup>US-</sup> 20020082554	Jun-27-2002	Lenarz et al.	
		US-			

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	<b>-</b> -6
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	T"
	AL	WO 97/38698	Oct-23-97	Manning et al.		
	AM	WO 2004/022069	Mar-18-04	Puel et al.		_
	<u> </u>					┝
	_					

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

/	te for form 1449/PTO				Complete if Known
Substitu	10 101 101111 1445/F1O			Application Number	10/812,298
INFO	ORMATION	DIS	CLOSURE	Filing Date	March 29, 2004
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	Matthieu Guitton
		_4		Art Unit	Not yet assigned
	(Use as many sheets as necessary)			Examiner Name	Not yet assigned
Sheet	2	of	4	Attorney Docket Number	AUR-2001US01

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No. <sup>1</sup>	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AR	Vesterarger V., Brit. Med. J. 314(7082): 728-731 (1997).	
	AS	Nicolas-Puel et al., Int. Tinn. J. 8(1): 37-44 (2002).	
	AT	Olney et al., J. Neuro. Exp. Neurol. 31(3): 464-488 (1972).	
	AU	Puel, J.L., Prog. Neurobiol. 47(6): 449-76 (1995).	
	AV	Pujol and Puel, Ann. NY Acad. Sci. 884: 249-254 (1999).	
	AW	Puel et al., Acta Otolaryngol. 117(2): 214-218 (1997).	
	AX	Puel et al., Audiol. Neurootol. 7(1): 49-54 (2002).	
	AY	Puel et al., C.R. Acad. Sci. III. 318(1): 67-75 (1995).	
	AZ	Sattler and Tymianski, Mol. Neurobiol. 24(1-3): 107-129 (2001).	
	AR2	D'Aldin et al., Int. J. Dev. Neurosci. 15(4-5): 619-629 (1997).	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known
	Application Number	10/812,298
INFORMATION DISCLOSURE	Filing Date	March 29, 2004
STATEMENT BY APPLICANT	First Named Inventor	Matthieu Guitton
(Use as many sheets as necessary)	Art Unit	Not yet assigned
(Use as many sneets as necessary)	Examiner Name	Not yet assigned
Sheet 3 of 4	Attorney Docket Number	AUR-2001US01

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	·
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AS2	Duan et al., Proc. Natl. Acad. Sci. USA 97 (13): 7597-7602 (2000).	
	AT2	Puel et al., J. Comp. Neurol. 341 (2): 241-256 (1994).	
	AU2	Ruel et al., J. Physiol. London 518: 667-680 (1999).	
	AV2	Guitton et al., J. of Neuroscience 23(9): 3944-3952 (2003).	
	AW2	Cazals Y., Prog. Neurobiol. 62: 583-631 (2000).	
,	AX2	Vane and Botting, Am. J. Med. 104: 2S-8S (1998).	
	AY2	Miller et al., Nature 355: 722-725 (1992).	
- 174.**	AZ2	Horimoto et al., NeuroReport 7: 2463-2467 (1996).	
	AR3	Casado and Ascher, J. Physiol. 513: 317-330 (1998).	
	AS3	Yamakura and Shimoji, Prog. Neurobiol. 59: 279-298 (1999).	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	Substitute for form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)	Complete if Known			
Cubsulu	10 10/11/11/14/5/1			Application Number	10/812,298
INF	ORMATION	DIS	CLOSURE	Filing Date	March 29, 2004
STA	TEMENT E	Y A	PPLICANT	First Named Inventor	Matthieu Guitton
	(Usa as many sho	ate ae n	occessar)	Art Unit	Not yet assigned
	(Ose as many sne	ets as 11	ecessary)	Examiner Name	Not yet assigned
Sheet	4	of	4	Attorney Docket Number	AUR-2001US01

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AT3	Kemp and McKernan, Nature Neuro. 5, supplement: 1039-1042 (2002).	
	AU3	Chen et al., Audiol. Neurootol. 8: 49-56 (2003).	
	AV3	Vollenweider et al., Eur. Neuropsychopharmacol. 7: 25-38 (1997).	
	AW3	Silverstein et al., Otolaryngology - Head and Neck Surgery 120(5): 649-655 (1999).	
<u>,</u>	AX3	Balough et al., Otolaryngology - Head and Neck Surgery 119(5): 427-431 (1998).	
	AY3	Hoffer et al., Otolaryngologic Clinics of North America 36(2): 353-358 (2003).	
	AZ3	Wang et al., J. of Neuroscience 23(24): 8596-8607 (2003).	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.